Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus PULMOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus PULMOLITE.
INDIUM IN 111 OXYQUINOLINE vs PULMOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical